Consistent with previous studies, the cellular effects of DLBCL cells caused by CFI-400945 treatment peaked at concentrations of 20–50 nM, indicating that this influence was unlikely caused by Aurora kinase B inhibition. Here, AURKB is linked to diffuse large B-cell lymphoma.